Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15139MR)

This product GTTS-WQ15139MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15139MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3094MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ6679MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ2665MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ12092MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ942MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ6774MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ13203MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11890MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW